Case Report

McKittrick-Wheelock Syndrome Presenting with Acute Kidney Injury and Metabolic Alkalosis: Case Report and Narrative Review

Mireille Caron ^(b), ¹ Charles-Etienne Dubrûle, ² François Letarte, ³ Valéry Lemelin, ⁴ and Alexandre Lafleur^{2,5}

¹Faculty of Medicine, Laval University, Québec City, QC, Canada

²Department of Internal Medicine, CHU de Québec, Québec City, QC, Canada

³Department of Surgery, CHU de Québec, Québec City, QC, Canada

⁴Department of Gastroenterology, CHU de Québec, Québec City, QC, Canada

⁵Faculty of Medicine, Department of Medicine, Laval University, Québec City, QC, Canada

Correspondence should be addressed to Mireille Caron; mireille.caron.5@ulaval.ca

Received 25 October 2018; Accepted 9 January 2019; Published 31 January 2019

Academic Editor: Chia-Tung Shun

Copyright © 2019 Mireille Caron et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

A rare combination of severe volume depletion and electrolyte imbalance caused by a rectal villous adenoma is often referred to as the McKittrick-Wheelock syndrome. Patients usually seek medical care because of chronic hypersecretory diarrhea and display renal failure, metabolic acidosis, hyponatremia, and hypokalemia. We report the case of a 68-year-old woman who presented with this condition but showed unusual features such as severe hypokalemia and metabolic alkalosis, without diarrhea. She subsequently underwent transanal endoscopic microsurgery (TEMS), an innovative procedure in the management of large rectal adenomas. We also provide a narrative review of the literature on this rare entity.

1. Introduction

Most colorectal polyps are asymptomatic. However, a minority of adenomas may present with rectal bleeding, tenesmus, or even chronic diarrhea, which can lead to dehydration. A rare combination of severe volume depletion and electrolyte imbalance caused by a large rectal villous adenoma is often referred to as the McKittrick-Wheelock syndrome. Here we outline the case of a 68-year-old woman who developed this condition and review the literature on this topic. This report aims to increase awareness for this reversible but potentially lethal entity, especially when atypical features are present. Prior informed patient consent was obtained for publication of the case details.

2. Case Report

A 68-year-old woman with no previous medical history presented to the Emergency Room for weakness, dizziness,

and nausea of a few days duration. At presentation, blood pressure was 133/64, heart rate 51, temperature 36.8, and respiratory rate 16. An EKG showed sinus bradycardia, a prolonged QT interval, and prominent U waves (Figure 1). Blood tests revealed a creatinine of 338 μ mol/L. Potassium was 1,7 meq/L, sodium 120 meq/L, chloride 61 meq/L, pH 7.57, and bicarbonates 43 meq/L. Urinalysis was as follows: sodium, 6 meq/L; potassium, 28 meq/L; chloride, <10 meq/L. Serum renin and aldosterone were ordered upon admission; after a few days delay, the values came back elevated at 152 ng/L and 3000 pmol/L, respectively. An abdominal ultrasound showed normal kidneys and bladder and a moderate quantity of fluid in the rectum. A renal scintigraphy revealed bilateral moderately severe renal dysfunction, which was suggestive of acute kidney injury. Diuresis was overall preserved (682 cc over the first 24 hours) and improved after fluid resuscitation (1800 cc on day 2). The hemodynamic and electrolyte status were normalized following the administration of approximately 3.5 liters of normal saline intravenously (IV), 180 mEq of oral



FIGURE 1: Electrocardiogram performed on first visit. The U waves are seen in precordial derivations (arrows). In V2-V3-V4, they are fused to the end of the T waves. In V5-V6, inverted T waves are followed by subtle U waves. The pseudo-prolonged QT interval actually results from the measurement of a long QU interval. HR = heart rate; bpm = beats per minute; QT = QT interval; QTc = corrected QT interval; ms = milliseconds.

	Day 0 (admission)	Day 7 (discharge)	Day 9 (readmission)	Day 14 (PO #4)
WBC count (x $10^9/L$)	11.5	13.1	26.9	7.1
Hemoglobin (g/L)	152	127	137	90
Platelets (x10 ⁹ /L)	191	176	330	226
Creatinine (mol/L)	338	113	127	59
Sodium (meq/L)	120	128	112	136
Potassium (meq/L)	1.7	2.7	2.5	3.8
Chloride (meq/L)	61	82	63	106
pН	7.57	7.54	7.53	
Bicarbonates (meq/L)	43	35	34	
Urine sodium (meq/L)	6	<5	<5	
Urine potassium (meq/L)	28.9	42.4	21.2	
Urine chloride (meq/L)	<10	<10	<10	
Serum renin (ng/L)	152			
Serum aldosterone (pmol/L)	3000			

PO #4 = postoperative day 4; WBC = white blood cell.

and 180 mEq of IV potassium chloride over the first two days. Awaiting some laboratory results, a working diagnosis of renal tubulopathy was later disproved. The patient was discharged one week later with spironolactone and potassium chloride tablets and was referred to a nephrologist to plan further investigations.

She presented two days later with a recurrence of symptoms, new-onset atrial fibrillation, and severe hyponatremia at 113 meq/L. Although the patient denied having diarrhea, a thorough questionnaire revealed a three-month history of soft stools and mucoid discharge per rectum. At digital rectal examination, a soft mass was palpated. Sigmoidoscopy revealed the presence of a large secretory villous adenoma extending from anal margin to 10 cm. This confirmed the diagnosis of the McKittrick-Wheelock syndrome (MWS). Multiple biopsies showed a tubulovillous adenoma with focal high-grade dysplasia.

The patient underwent transanal endoscopic microsurgery (TEMS) successfully (Figure 2). However, atrial fibrillation recurred postoperatively and consequently she was started on low-molecular weight heparin and warfarin. Creatinine and electrolytes all normalized after surgery. Table 1 shows the evolution of laboratory values from initial admission to postoperative day 4. She was discharged on postoperative day 6. Final pathology confirmed clear resection margins and the absence of invasive adenocarcinoma.

Age 63.5 Man (years) 63.5 Max (years) 26 Max (years) 84 ND 3 Sex, N (%) 7 Female 24 (49.0) ND 3 (6.1) Henodynamic state, N (%) 16 (32.7) Stable 3 (6.1) Hypotension and/or tachycardia 16 (32.7) Stable 3 (6.1) ND 30 (61.2) Diarrhea, N (%) 42 (85.7) YES 42 (85.7) NO 1 (2.0) ND 6 (12.2) Remarkable features, N (%) 1 (2.0) Prolapse 3 (6.1) Intersusception 1 (2.0) Reversible diabetes 2 (4.1) Infectious endocarditis (E. Faecalis) 1 (2.0) Familial adenomatous polyposis syndrome 1 (2.0) Cronkhite-Canada syndrome 1 (2.0) Lab tests 359 (1440; 447.75); 21 NI Median creatinine, µmol/L (max; IQR) 359 (1440; 447.75); 21 NI Median creatinine, µmol/L (mix
Mean (years) 63.5 Min (years) 26 Max (years) 84 ND 3 Sex, N (%) 7 Female 24 (49.0) ND 3 (6.1) Hemodynamic state, N (%) 16 (32.7) Stable 3 (6.1) Hypotension and/or tachycardia 16 (32.7) Stable 3 (6.1) ND 30 (61.2) Diarnhea, N (%) 42 (85.7) YES 42 (85.7) NO 1 (2.0) ND 6 (12.2) Remarkable features, N (%) 1 (2.0) Prolapse 3 (6.1) Intussusception 1 (2.0) Reversible diabetes 2 (4.1) Infectious endocarditis (E. Faecalis) 1 (2.0) Cronkhite-Canada syndrome 1 (2.0) Cronkhite-Canada syndrome 1 (2.0) Lab tests 359 (1440; 447.75); 21 NI Median creatinine, µmol/L (max; IQR) 359 (1440; 447.75); 21 NI Median creatinine, µmol/L (mix; IQR) 26 (1.3; 0.75); 16 ND
Min (years) 26 Max (years) 84 ND 3 Sex, N (%) 1 Female 24 (49.0) ND 3 (6.1) Hemodynamic state, N (%) 16 (32.7) Stable 3 (6.1) ND 30 (61.2) Diarrhea, N (%) 24 (85.7) YES 42 (85.7) NO 1 (2.0) ND 6 (12.2) Remarkable features, N (%) 6 (12.2) Prolapse 3 (6.1) Infectious endocarditis (E. Faecalis) 1 (2.0) Reversible diabetes 2 (4.1) Infectious endocarditis (E. Faecalis) 1 (2.0) Familial adenomatous polyposis syndrome 1 (2.0) Cronkhite-Canada syndrome 1 (2.0) Lab tests 359 (1440; 447.75); 21 NI Median creatinine, µmol/L (mix; IQR) 359 (1440; 447.75); 21 NI Median creatinine, µmol/L (mix; IQR) 359 (1440; 447.75); 21 NI Median coloride, meq/L (min; IQR) 26 (1.3; 0.75); 16 ND Median coloride, meq/L (min; IQR) 67 (<45; 22.5); 36 ND
Max (years) 84 ND 3 Sex, N (%) 1 Female 24 (49.0) ND 3 (6.1) Hemodynamic state, N (%) 1 Hypotension and/or tachycardia 16 (32.7) Stable 3 (6.1) ND 30 (6.2) Diarrhea, N (%) 24 (85.7) NO 1 (2.0) ND 6 (12.2) Remarkable features, N (%) 1 (2.0) Prolapse 3 (6.1) Influctions endocarditis (<i>E. Faecalis</i>) 1 (2.0) Reversible diabetes 2 (4.1) Infectious endocarditis (<i>E. Faecalis</i>) 1 (2.0) Familial adenomatous polyposis syndrome 1 (2.0) Cronkhite-Canada syndrome 1 (2.0) Lab test 10 Median creatinine, µmol/L (max; IQR) 359 (1440; 447.75); 21 NI Median coloride, meq/L (min; IQR) 67 (<45; 22.5); 36 ND
ND 3 Sex, N (%) $=$ Female 24 (49.0) ND 3 (6.1) Hemodynamic state, N (%) 16 (32.7) Stable 3 (6.1) ND 30 (61.2) Diarrhea, N (%) 42 (85.7) NO 1 (2.0) Diarrhea, N (%) 42 (85.7) NO 1 (2.0) ND 6 (12.2) Remarkable features, N (%) 6 (12.2) Prolapse 3 (6.1) Intussusception 1 (2.0) Reversible diabetes 2 (4.1) Infectious endocarditis (E. Faecalis) 1 (2.0) Reversible diabetes 1 (2.0) Cronkhite-Canada syndrome 1 (2.0) Cronkhite-Canada syndrome 1 (2.0) Lab tests 359 (1440; 447.75); 21 NI Median colum, meq/L (min; IQR) 359 (1440; 447.75); 21 NI Median colum, meq/L (min; IQR) 18 (93; 13.5; 20 ND Median coloride, meq/L (min; IQR) 67 (<45; 22.5); 36 ND
Sex, N (%) 24 (49.0) ND 3 (6.1) Hemodynamic state, N (%) 16 (32.7) Stable 3 (6.1) ND 30 (6.1) ND 30 (6.1) ND 30 (6.1) Diarrhea, N (%) 30 (6.2) Diarrhea, N (%) 42 (85.7) NO 1 (2.0) ND 6 (12.2) Remarkable features, N (%) 1 (2.0) Prolapse 3 (6.1) Intussusception 1 (2.0) Reversible diabetes 2 (4.1) Infectious endocarditis (E. Faecalis) 1 (2.0) Familial adenomatous polyposis syndrome 1 (2.0) Cronkhite-Canada syndrome 1 (2.0) Lab tests 359 (1440; 447.75); 21 NI Median creatinine, µmol/L (mix; IQR) 359 (1440; 447.75); 21 NI Median sodium, meq/L (mix; IQR) 359 (1440; 447.75); 21 NI Median creatinine, µmol/L (mix; IQR) 6 (2.2); 31 (5.6); 38 ND Median bicarbonates, meq/L (mix; IQR) 6 (2.2); 31 (5.6); 38 ND Median bicarbonates, meq/L (mix; IQR) 6 (2.2); 42 ND
Female $24 (49.0)$ ND $3 (6.1)$ Hemodynamic state, N (%) 16 (32.7) Stable $3 (6.1)$ ND $3 (6.1)$ ND $3 (6.1)$ ND $3 (6.1)$ ND $3 (6.1)$ Diarrhea, N (%) $42 (85.7)$ NO $1 (2.0)$ ND $6 (12.2)$ Remarkable features, N (%) $6 (12.2)$ Prolapse $3 (6.1)$ Intussusception $1 (2.0)$ Reversible diabetes $2 (4.1)$ Infectious endocarditis (<i>E. Faecalis</i>) $1 (2.0)$ Familial adenomatous polyposis syndrome $1 (2.0)$ Cronkhite-Canada syndrome $1 (2.0)$ Lab tests $359 (1440; 447.75); 21 NI$ Median creatinine, μ mol/L (max; IQR) $359 (1440; 447.75); 21 NI$ Median sodium, meq/L (min; IQR) $2.6 (1.3, 0.75); 16 ND$ Median boloride, meq/L (min; IQR) $67 (<45; 2.25); 36 ND$ Median boloride, meq/L (min; IQR) $67 (<45; 2.25); 36 ND$ Median biordonates, meq/L (min; IQR) $6 (12.2); 42 ND$
ND 3 (6.1) Hemodynamic state, N (%) 16 (32.7) Stable 3 (6.1) ND 3 (6.1) Diarrhea, N (%) 42 (85.7) NO 1 (2.0) ND 6 (12.2) Remarkable features, N (%) 6 (12.2) Prolapse 3 (6.1) Intussusception 1 (2.0) Reversible diabetes 2 (4.1) Infectious endocarditis (<i>E. Faecalis</i>) 1 (2.0) Familial adenomatous polyposis syndrome 1 (2.0) Cronkhite-Canada syndrome 1 (2.0) Lab tests 11 (2.0) Median creatinine, μ mol/L (max; IQR) 359 (1440; 447.75); 21 NI Median sodium, meq/L (min; IQR) 359 (1440; 447.75); 21 NI Median potassium, meq/L (min; IQR) 2.6 (1.3; 0.75); 16 ND Median boloride, meq/L (min; IQR) 2.6 (1.3; 0.75); 16 ND Median boloride, meq/L (min; IQR) 67 (<45; 2.2; 5); 36 ND
Hemodynamic state, N (%)16 (32.7)Stable3 (6.1)ND30 (61.2)Diarrhea, N (%) 30 (62.2)YES42 (85.7)NO1 (2.0)ND6 (12.2)Remarkable features, N (%) 1 (2.0)Prolapse3 (6.1)Intussusception1 (2.0)Reversible diabetes2 (4.1)Infectious endocarditis (E. Faecalis)1 (2.0)Familial adenomatous polyposis syndrome1 (2.0)Cronkhite-Canada syndrome1 (2.0)Lab tests359 (1440; 44775); 21 NIMedian creatinine, µmol/L (ma; IQR)259 (1440; 44775); 21 NIMedian potassium, meq/L (min; IQR)67 (c45; 22.5); 36 NDMedian chloride, meq/L (min; IQR)67 (c45; 22.5); 36 NDMedian bicarbonates, meq/L (min; IQR)67 (c45; 22.5); 36 ND<
Hypotension and/or tachycardia16 (32.7)Stable3 (6.1)ND30 (61.2)Diarrhea, N (%) $42 (85.7)$ YES42 (85.7)NO1 (2.0)ND6 (12.2)Remarkable features, N (%) 7 Prolapse3 (6.1)Intussusception1 (2.0)Reversible diabetes2 (4.1)Infectious endocarditis (E. Faecalis)1 (2.0)Familial adenomatous polyposis syndrome1 (2.0)Cronkhite-Canada syndrome1 (2.0)Lab tests $359 (1440; 447.75); 21 NIMedian creatinine, \mumol/L (mi; IQR)359 (1440; 447.75); 21 NIMedian potassium, meq/L (mi; IQR)2.6 (1.3; 0.75); 16 NDMedian chloride, meq/L (mi; IQR)67 (<45; 22.5); 36 NDMedian bicarbonates, meq/L (mi; IQR)67 (<45; 22.5); 36 NDMedian bicarbonates, meq/L (mi; IQR)61 (2.2); 42 ND$
Stable 3 (6.1) ND 30 (61.2) Diarrhea, N (%) 42 (85.7) YES 42 (85.7) NO 1 (2.0) ND 6 (12.2) Remarkable features, N (%) 7 Prolapse 3 (6.1) Intussusception 1 (2.0) Reversible diabetes 2 (4.1) Infectious endocarditis (E. Faecalis) 1 (2.0) Familial adenomatous polyposis syndrome 1 (2.0) Cronkhite-Canada syndrome 1 (2.0) Lab tests 359 (1440; 447.75); 21 NI Median creatinine, μ mol/L (mir, IQR) 359 (1440; 447.75); 21 NI Median potassium, meq/L (min; IQR) 2.6 (1.3; 0.75); 16 ND Median creatinine, μ mol/L (mir, IQR) 2.6 (1.3; 0.75); 16 ND Median chloride, meq/L (min; IQR) 67 (<45; 22.5); 36 ND
ND 30 (6.2) Diarrhea, N (%) 42 (85.7) NO 1 (2.0) ND 6 (12.2) Remarkable features, N (%) 1 (2.0) Prolapse 3 (6.1) Intussusception 1 (2.0) Reversible diabetes 2 (4.1) Infectious endocarditis (E. Faecalis) 1 (2.0) Familial adenomatous polyposis syndrome 1 (2.0) Cronkhite-Canada syndrome 1 (2.0) Lab tests 359 (1440; 447.75); 21 NI Median creatinine, µmol/L (max; IQR) 359 (1440; 447.75); 21 NI Median rotatine, µmol/L (max; IQR) 359 (1440; 447.75); 21 NI Median choride, meq/L (min; IQR) 67 (<45; 22.5); 36 ND
$\begin{array}{llllllllllllllllllllllllllllllllllll$
YES $42 (85.7)$ NO $1 (2.0)$ ND $6 (12.2)$ Remarkable features, N (%) 7 Prolapse $3 (6.1)$ Intussusception $1 (2.0)$ Reversible diabetes $2 (4.1)$ Infectious endocarditis (E. Faecalis) $1 (2.0)$ Familial adenomatous polyposis syndrome $1 (2.0)$ Cronkhite-Canada syndrome $1 (2.0)$ Lab tests $359 (1440; 447.75); 21 NI$ Median creatinine, μ mol/L (max; IQR) $359 (1440; 447.75); 20 ND$ Median sodium, meq/L (min; IQR) $118 (93; 13.5); 20 ND$ Median chloride, meq/L (min; IQR) $2.6 (1.3; 0.75); 16 ND$ Median chloride, meq/L (min; IQR) $67 (<45; 22.5); 36 ND$ Median bicarbonates, meq/L (min; max; IQR) $16 (72; 31; 15.6); 38 ND$ Acidosis present (pH <7,35), N (%)
NO1 (2.0)ND6 (12.2)Remarkable features, N (%)Prolapse3 (6.1)Intussusception1 (2.0)Reversible diabetes2 (4.1)Infectious endocarditis (E. Faecalis)1 (2.0)Familial adenomatous polyposis syndrome1 (2.0)Cronkhite-Canada syndrome1 (2.0)Lab tests359 (1440; 447.75); 21 NIMedian creatinine, μ mol/L (max; IQR)359 (1440; 447.75); 21 NIMedian sodium, meq/L (min; IQR)118 (93; 13.5); 20 NDMedian potassium, meq/L (min; IQR)2.6 (1.3; 0.75); 16 NDMedian chloride, meq/L (min; IQR)67 (<45; 22.5); 36 ND
ND 6 (1.2)Remarkable features, N (%) 7 rolapse 3 (6.1)Prolapse 3 (6.1) 1 (2.0)Intussusception 1 (2.0)Reversible diabetes 2 (4.1)Infectious endocarditis (E. Faecalis) 1 (2.0)Familial adenomatous polyposis syndrome 1 (2.0)Cronkhite-Canada syndrome 1 (2.0)Lab tests 1 (2.0)Median creatinine, μ mol/L (max; IQR) 359 (1440; 447.75); 21 NIMedian potassium, meq/L (min; IQR) 2.6 (1.3; 0.75); 16 NDMedian chloride, meq/L (min; IQR) 67 (<45; 22.5); 36 ND
Remarkable features, N (%)Prolapse3 (6.1)Intussusception1 (2.0)Reversible diabetes2 (4.1)Infectious endocarditis (E. Faecalis)1 (2.0)Familial adenomatous polyposis syndrome1 (2.0)Cronkhite-Canada syndrome1 (2.0)Lab tests359 (1440; 447.75); 21 NIMedian creatinine, μ mol/L (max; IQR)359 (1440; 447.75); 20 NDMedian sodium, meq/L (min; IQR)2.6 (1.3; 0.75); 16 NDMedian chloride, meq/L (min; IQR)67 (<45; 22.5); 36 ND
Prolapse3 (6.1)Intussusception1 (2.0)Reversible diabetes2 (4.1)Infectious endocarditis (E. Faecalis)1 (2.0)Familial adenomatous polyposis syndrome1 (2.0)Cronkhite-Canada syndrome1 (2.0)Cronkhite-Canada syndrome1 (2.0)Lab tests359 (1440; 447.75); 21 NIMedian creatinine, μ mol/L (max; IQR)359 (1440; 447.75); 21 NIMedian sodium, meq/L (min; IQR)118 (93; 13.5); 20 NDMedian potassium, meq/L (min; IQR)2.6 (1.3; 0.75); 16 NDMedian chloride, meq/L (min; IQR)67 (<45; 22.5); 36 ND
Intussusception1 (2.0)Reversible diabetes2 (4.1)Infectious endocarditis (<i>E. Faecalis</i>)1 (2.0)Familial adenomatous polyposis syndrome1 (2.0)Cronkhite-Canada syndrome1 (2.0) <i>Lab tests</i> 1 (2.0)Median creatinine, μ mol/L (max; IQR)359 (1440; 447.75); 21 NIMedian sodium, meq/L (min; IQR)118 (93; 13.5); 20 NDMedian potassium, meq/L (min; IQR)2.6 (1.3; 0.75); 16 NDMedian chloride, meq/L (min; IQR)67 (<45; 22.5); 36 ND
Reversible diabetes2 (4.1)Infectious endocarditis (E. Faecalis)1 (2.0)Familial adenomatous polyposis syndrome1 (2.0)Cronkhite-Canada syndrome1 (2.0)Lab tests1 (2.0)Median creatinine, μ mol/L (max; IQR)359 (1440; 447.75); 21 NIMedian sodium, meq/L (min; IQR)118 (93; 13.5); 20 NDMedian potassium, meq/L (min; IQR)2.6 (1.3; 0.75); 16 NDMedian chloride, meq/L (min; IQR)67 (<45; 22.5); 36 ND
Infectious endocarditis (E. Faecalis)1 (2.0)Familial adenomatous polyposis syndrome1 (2.0)Cronkhite-Canada syndrome1 (2.0)Lab tests1 (2.0)Median creatinine, μ mol/L (max; IQR)359 (1440; 447.75); 21 NIMedian sodium, meq/L (min; IQR)118 (93; 13.5); 20 NDMedian potassium, meq/L (min; IQR)2.6 (1.3; 0.75); 16 NDMedian chloride, meq/L (min; IQR)67 (<45; 22.5); 36 ND
Familial adenomatous polyposis syndrome1 (2.0)Cronkhite-Canada syndrome1 (2.0)Lab tests1 (2.0)Median creatinine, μ mol/L (max; IQR)359 (1440; 447.75); 21 NIMedian sodium, meq/L (min; IQR)118 (93; 13.5); 20 NDMedian potassium, meq/L (min; IQR)2.6 (1.3; 0.75); 16 NDMedian chloride, meq/L (min; IQR)67 (<45; 22.5); 36 ND
Cronkhite-Canada syndrome1 (2.0)Lab tests1 (2.0)Median creatinine, μ mol/L (max; IQR)359 (1440; 447.75); 21 NIMedian sodium, meq/L (min; IQR)118 (93; 13.5); 20 NDMedian potassium, meq/L (min; IQR)2.6 (1.3; 0.75); 16 NDMedian chloride, meq/L (min; IQR)67 (<45; 22.5); 36 NDMedian bicarbonates, meq/L (min; max; IQR)16 (7.2; 31; 15.6); 38 NDAcidosis present (pH <7,35), N (%)6 (12.2); 42 ND
Lab tests Median creatinine, μ mol/L (max; IQR) 359 (1440; 447.75); 21 NI Median sodium, meq/L (min; IQR) 118 (93; 13.5); 20 ND Median potassium, meq/L (min; IQR) 2.6 (1.3; 0.75); 16 ND Median chloride, meq/L (min; IQR) 67 (<45; 22.5); 36 ND
Median creatinine, μ mol/L (max; IQR) 359 (1440; 447.75); 21 NI Median sodium, meq/L (min; IQR) 118 (93; 13.5); 20 ND Median potassium, meq/L (min; IQR) 2.6 (1.3; 0.75); 16 ND Median chloride, meq/L (min; IQR) 67 (<45; 22.5); 36 ND
Median sodium, meq/L (min; IQR) 118 (93; 13.5); 20 ND Median potassium, meq/L (min; IQR) 2.6 (1.3; 0.75); 16 ND Median chloride, meq/L (min; IQR) 67 (<45; 22.5); 36 ND
Median potassium, meq/L (min; IQR) 2.6 (1.3; 0.75); 16 ND Median chloride, meq/L (min; IQR) 67 (<45; 22.5); 36 ND
Median chloride, meq/L (min; IQR) 67 (<45; 22.5); 36 ND
Median bicarbonates, meq/L (min; max; IQR) 16 (7.2; 31; 15.6); 38 ND Acidosis present (pH <7,35), N (%)
Acidosis present (pH <7,35), N (%) 6 (12.2); 42 ND
Alkalosis present (pH >7,45), N (%) 1 (2.0); 42 ND
Pathology, N (%)
Benign 13 (26.5)
HGD/Cis 11 (22.4)
Adenocarcinoma 9 (18.4)
Other* 1 (2.0)
ND 15 (30.6)
Management, N (%)
Surgery [†] 31 (63.3)
Minimally invasive surgery [†] 9 (18.4)
Medical [†] 5 (10.2)
No treatment 4 (8.2)
ND 2 (4.1)

TABLE 2: Demographic and clinical characteristics of patients.

*Pathology showed a neuroendocrine tumor [1].

[†]One patient was treated medically before surgery [2]; another patient underwent transanal minimally invasive surgery (TAMIS) and then surgery one year later for recurrence [3].

ND = not determined; min = minimum value; max = maximum value; IQR = interquartile range; HGD = high grade dysplasia; Cis = carcinoma in situ.



FIGURE 2: Macroscopic aspect of villous adenoma.

3. Discussion

A syndrome of severe volume depletion and electrolyte imbalance caused by a villous adenoma was first described by McKittrick and Wheelock in 1954 [4]. Prostaglandin E2 and cyclic AMP have both been implicated as secretagogues produced by the adenomatous tissue in cases of MWS [5].

This syndrome occurs exclusively with tumors located in the rectum; according to an early series of 48 cases, only eight were above the reach of a finger [4]. A possible explanation for this finding is that distal localization of the tumor precludes reabsorption of the secreted fluid by the colonic mucosa. Such lesions can release up to 4000 cc of clear, thin mucus containing up to 11 grams of sodium daily [4, 6].

At least 132 cases had been reported by 2013 [7]. However, very few authors have reviewed published literature on this topic [3, 8]. We conducted a first search on PubMed using "McKittrick" AND "Wheelock", which lead to 57 results. Of those, four were irrelevant, 12 were not published in English language, one was a retrospective study, and one article was an update on a previous case.

We launched a second search using "Secretory" AND "Villous" AND "Rectum" AND "Adenoma", which lead to 15 results. Five of them were not published in English language, and eight were already included with first search. The two remaining articles were added to the review, for a total of 41 publications and 49 MWS cases in English language.

Table 2 shows the demographic and clinical characteristics of the 49 included patients. Mean age was 63.5 years and at least 48% were women. A vast majority of patients reported nonbloody diarrhea of variable duration. When mentioned, more patients were acidotic at presentation [9– 13]. Malignant pathology (adenocarcinoma) was found in 18% of examined tumors. Of interest, two patients with a history of diabetes returned to normal glucose levels after tumor resection; it was hypothesized that diabetes was likely due to secondary hyperaldosteronism [14, 15]. A majority of patients (62%) received definitive treatment with invasive surgery, such as abdominal perineal resection with colostomy or low anterior resection. However, we noticed an increasing use of minimally invasive techniques in more recent reports (18%), including TEMS, transanal minimally invasive surgery (TAMIS), endoscopic mucosal resection (EMR), and endoscopic submucosal dissection (ESD). Empiric medical treatment with indomethacin with or without octreotide was tried in five patients [1, 2, 16–18]. Indomethacin was shown to reduce diarrhea by 50% in at least one patient, but at the cost of an increase in creatinine [2]. The benefit of octreotide is unclear; its use even resulted in a 25% increase in diarrhea in one patient, when used without indomethacin [2].

One of the unique features in our case was the absence of diarrhea. Additionally, our patient presented with a predominant metabolic alkalosis; this uncommon finding was reported in only one other case [19]. Most secretory villous adenomas of the colon cause a hyperchloremic metabolic acidosis because they produce large volumes of a potassium, bicarbonate-rich fluid. Moreover, lactate accumulation and acute kidney injury may contribute to the acidosis. However, 10 to 20% of these tumors secrete chloride rather than bicarbonate, which results in metabolic alkalosis [20]. Volume depletion also leads to secondary hyperaldosteronism, enhancing hypokalemia and alkalosis. Elevated serum renin and aldosterone in our patient supported this pathophysiology. As the etiology of normotensive hypokalemic metabolic alkalosis is not always apparent from the history, a spot urine sample and a 24-hour urine collection can be helpful in such situations. In our case, the initial finding of low urinary chloride concentration pointed toward an extrarenal loss.

In conclusion, McKittrick-Wheelock syndrome is rare and potentially lethal. Acute kidney injury and metabolic disturbances are usually reversible but will quickly recur until tumor resection is performed. Diarrhea is often but not always a prominent symptom; clinicians should question specifically for rectal mucoid discharge since patients will avoid mentioning this embarrassing symptom. Minimally invasive approaches are increasingly used in the management of this condition.

Consent

Prior informed patient consent was obtained for publication of the case details.

Conflicts of Interest

The authors have no intellectual or financial conflicts of interest.

Authors' Contributions

According to the 2017 ICMJE Recommendations, all authors have contributed sufficiently to the work to be listed as authors and have approved the manuscript for submission.

Acknowledgments

We would like to thank the patient who provided permission to share her case. We thank the internal medicine, gastroenterology, and general surgery departments of CHU de Québec.

References

- S. G. Nakhla, T. T. Murakami, and S. Sundararajan, "Poorly differentiated neuroendocrine tumor of the rectum coexistent with giant rectal villous adenoma presenting as mckittrickwheelock syndrome," *Case Reports in Oncological Medicine*, vol. 2015, Article ID 242760, 4 pages, 2015.
- [2] A. H. M. Smelt, A. E. Meinders, K. Hoekman, W. A. Noort, and M. J. N. C. Keirse, "Secretory diarrhea in villous adenoma of rectum: Effect of treatment with somatostatin and indomethacin," *Prostaglandins & Other Lipid Mediators*, vol. 43, no. 6, pp. 567– 572, 1992.
- [3] A. E. van der Pool, E. J. de Graaf, M. Vermaas, R. M. Barendse, and P. G. Doornebosch, "McKittrick wheelock syndrome treated by transanal minimally invasive surgery: a singlecenter experience and review of the literature," *Journal of Laparoendoscopic & Advanced Surgical Techniques*, vol. 28, no. 2, pp. 204–208, 2018.
- [4] L. S. McKittrick and F. C. Wheelock, "Carcinoma of the colon," Diseases of the Colon & Rectum, vol. 40, no. 12, pp. 1494–1496, 1997.
- [5] H. Jacob, D. Schlondorff, G. S. Onge, and L. H. Bernstein, "Villous adenoma depletion syndrome - Evidence for a cyclic nucleotide-mediated diarrhea," *Digestive Diseases and Sciences*, vol. 30, no. 7, pp. 637–641, 1985.
- [6] M. J. Raphael, C. M. McDonald, and A. S. Detsky, "McKittrick-Wheelock syndrome," *Canadian Medical Association Journal*, vol. 187, no. 9, pp. 676–678, 2015.
- [7] P. Nicholson and C. Naugler, "McKittrick-Wheelock syndrome may represent the extreme of a normally distributed continuum of secretory activity in colorectal villous adenomas," *Clinica Chimica Acta*, vol. 436, pp. 9-10, 2014.
- [8] S. Malik, B. Mallick, K. Makkar, V. Kumar, V. Sharma, and S. S. Rana, "Malignant McKittrick-Wheelock syndrome as a cause of acute kidney injury and hypokalemia: Report of a case and review of literature," *Intractable and Rare Diseases Research*, vol. 5, no. 3, pp. 218–221, 2016.
- [9] R. M. Learney, P. Ziprin, P. A. Swift, and O. D. Faiz, "Acute renal failure in association with community-acquired clostridium difficile infection and Mckittrick-Wheelock syndrome," *Case Reports in Gastroenterology*, vol. 5, no. 2, pp. 438–444, 2011.
- [10] D. Lepur, I. Klinar, B. Miše, J. Himbele, Z. Vranjican, and B. Baršić, "McKittrick-Wheelock syndrome: A rare cause of diarrhoea," *European Journal of Gastroenterology & Hepatology*, vol. 18, no. 5, pp. 557–559, 2006.
- [11] Y. Maeshiro, Y. Yamaji, S. Inoue, and Y. Nakazato, "Prerenal uremia induced by severe diarrhea due to colon adenoma: a case of McKittrick–Wheelock syndrome in an elderly patient," *CEN Case Reports*, vol. 3, no. 1, pp. 75–79, 2014.
- [12] M. A. Podestà, D. Cucchiari, E. Merizzoli, U. Elmore, C. Angelini, and S. Badalamenti, "McKittrick-Wheelock syndrome: A rare cause of acute renal failure and hypokalemia not to be overlooked," *Renal Failure*, vol. 36, no. 5, pp. 811–813, 2014.
- [13] S. S. Garcia, P. V. Campos, M. Del Carmen Manzanares Campillo et al., "Hypersecretory villous adenoma as the

- [14] B. G. Challis, C. T. Lim, A. Cluroe, E. Cameron, and S. O'Rahilly, "The McKittrick–Wheelock syndrome: a rare cause of curable diabetes," *Endocrinology, Diabetes & Metabolism Case Reports*, vol. 2016, Article ID 160013, 2016.
- [15] E. I. Mois, F. Graur, R. Sechel, and N. Al-Hajjar, "Mckittrickwheelock syndrome: A Rare case report of acute renal failure," *Clujul Medical*, vol. 89, no. 2, pp. 301–303, 2016.
- [16] A. Dagan and P. Reissman, "Giant secretory villous adenoma of the rectum and sigmoid presenting as McKittrick-Wheelock syndrome," *International Journal of Colorectal Disease*, vol. 25, no. 7, pp. 909-910, 2010.
- [17] M. D. Kagan, K. Schmidt, and G. Sangha, "Indomethacin therapy effective in a patient with depletion syndrome from secretory villous adenoma," *BMJ Case Reports*, vol. 2017, Article ID bcr2016217211, 2017.
- [18] K. Steven, P. Lange, K. Bukhave, and J. Rask-Madsen, "Prostaglandin E2-mediated secretory diarrhea in villous adenoma of rectum: Effect of treatment with indomethacin," *Gastroenterology*, vol. 80, no. 6, pp. 1562–1566, 1981.
- [19] V. Winstanley, M. A. Little, C. Wadsworth, P. Cohen, and N. M. Martin, "The McKittrick-Wheelock syndrome: A case of acute renal failure due to neoplastic cholera," *Renal Failure*, vol. 30, no. 4, pp. 469–473, 2008.
- [20] J. H. Galla, "Metabolic alkalosis," Journal of the American Society of Nephrology, vol. 11, no. 2, pp. 369–375, 2000.